Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorBarts & The London NHS Trust
About this trial
The main aim of the research is to investigate whether patients undergoing pulmonary vein isolation with catheter ablation for persistent atrial fibrillation (AF) will have lower rates of AF recurrence than those treated by DC cardioversion without an ablation procedure.
Eligibility criteria
Qualifiers
Ability to give informed consent
Age 18-85 years
Persistent AF (atrial fibrillation lasting > 7days) of total continuous duration <2 years as documented in medical notes.
Patients being considered for cardioversion.
Disqualifiers
Creatinine clearance (eGFR) < 30mls/min
Contraindication or unable to take anticoagulation
Uncontrolled hypertension
Contraindication for catheter ablation
Trial design
Treatments tested in this trial
- Pulmonary vein isolation
- DC Cardioversion
- Implantable loop recorder
- Femoral sheath insertion
Treatment groups
208 Participants
are divided into 2 treatment groupsLocations
1Barts Heart CentreEC1A 7BE, London United Kingdom
Sponsors and collaborators
Barts & The London NHS Trust
Lead sponsor
Source ClinicalTrials.gov